These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 20202690)

  • 1. Psychomotor performance and fitness to drive: the influence of psychiatric disease and its pharmacological treatment.
    De Las Cuevas C; Ramallo Y; Sanz EJ
    Psychiatry Res; 2010 Apr; 176(2-3):236-41. PubMed ID: 20202690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mental illness and road safety.
    de Las Cuevas Castresana C; Sanz Alvarez E
    Actas Esp Psiquiatr; 2009; 37(2):75-81. PubMed ID: 19401855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highway driving performance and cognitive functioning the morning after bedtime and middle-of-the-night use of gaboxadol, zopiclone and zolpidem.
    Leufkens TR; Lund JS; Vermeeren A
    J Sleep Res; 2009 Dec; 18(4):387-96. PubMed ID: 19552733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cognition and driving in schizophrenic patients under treatment with risperidone vs. haloperidol].
    Dittert S; Soyka M; Winter C; Möller HJ
    Fortschr Neurol Psychiatr; 1999 Nov; Suppl 2():S70-3. PubMed ID: 10598340
    [No Abstract]   [Full Text] [Related]  

  • 6. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of haloperidol and risperidone on psychomotor performance relevant to driving ability in schizophrenic patients compared to healthy controls.
    Soyka M; Winter C; Kagerer S; Brunnauer M; Laux G; Möller HJ
    J Psychiatr Res; 2005 Jan; 39(1):101-8. PubMed ID: 15504428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients.
    Lee SM; Chou YH; Li MH; Wan FJ; Yen MH
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1101-7. PubMed ID: 17475386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychomotor performance of psychiatric inpatients under therapy: assessment by paper and pencil tests.
    Agarwal AK; Kalra R; Natu MV; Dadhich AP; Deswal RS
    Hum Psychopharmacol; 2002 Mar; 17(2):91-3. PubMed ID: 12404697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative contribution of antipsychotics, negative symptoms and executive functions to social functioning in stable schizophrenia.
    Rocca P; Montemagni C; Castagna F; Giugiario M; Scalese M; Bogetto F
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):373-9. PubMed ID: 19211031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing cognitive and psychomotor performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain patients.
    Dagtekin O; Gerbershagen HJ; Wagner W; Petzke F; Radbruch L; Sabatowski R
    Anesth Analg; 2007 Nov; 105(5):1442-8, table of contents. PubMed ID: 17959980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance in normal subjects on a novel battery of driving-related sensory-motor and cognitive tests.
    Innes CR; Jones RD; Anderson TJ; Hollobon SG; Dalrymple-Alford JC
    Behav Res Methods; 2009 May; 41(2):284-94. PubMed ID: 19363169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cognitive impairments among older drivers: medical examination and driving test].
    Withaar FK; Brouwer WH; van Zomeren AH; Deelman BG
    Tijdschr Gerontol Geriatr; 2001 Aug; 32(4):160-4. PubMed ID: 11565419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of fitness to drive in people with Parkinson disease.
    Devos H; Vandenberghe W; Nieuwboer A; Tant M; Baten G; De Weerdt W
    Neurology; 2007 Oct; 69(14):1434-41. PubMed ID: 17909156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cognitive functioning in euthymic bipolar I and bipolar II patients.
    Dittmann S; Hennig-Fast K; Gerber S; Seemüller F; Riedel M; Emanuel Severus W; Langosch J; Engel RR; Möller HJ; Grunze HC
    Bipolar Disord; 2008 Dec; 10(8):877-87. PubMed ID: 19594503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
    Gibel A; Ritsner MS
    Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers.
    Otmani S; Demazières A; Staner C; Jacob N; Nir T; Zisapel N; Staner L
    Hum Psychopharmacol; 2008 Dec; 23(8):693-705. PubMed ID: 18763235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing cognition and psychomotor function under long-term treatment with controlled release oxycodone in non-cancer pain patients.
    Gaertner J; Radbruch L; Giesecke T; Gerbershagen H; Petzke F; Ostgathe C; Elsner F; Sabatowski R
    Acta Anaesthesiol Scand; 2006 Jul; 50(6):664-72. PubMed ID: 16987359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.